BrainStorm Cell Therapeutics Inc. Receives $800,000 Non-Dilutive Grant From Israel’s Office Of The Chief Scientist
Published: Dec 11, 2013
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a $800,000 non-dilutive grant from Israel’s Office of the Chief Scientist (OCS) for the year 2014. The grant is intended to support BrainStorm’s clinical and product development for its innovative stem cell therapy candidate NurOwn™.
Help employers find you! Check out all the jobs and post your resume.